Yükleniyor... / Loading...
This study examines how the drug Belinostat is processed by the body (pharmacokinetics) in patients with different UGT1A1*28 genotypes. Patients with advanced solid tumors or advanced blood cancers who have had at least one prior systemic therapy could take part. It was conducted in Phase 1 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Patient is diagnosed with advanced solid tumors or advanced hematological malignancy that is relapsed/refractory, for which no standard salvage therapy exists. 2. Patient must have received at least 1 prior systemic therapy for the current malignancy and has recovered from any toxicity of the prior therapy at screening. 3. Patient has adequate hematological and hepatic functions. Exclusion Criteria: 1. Patient is taking UGT1A1 inhibitors (eg, atazanavir, gemfibrozil, indinavir, ketoconazole, sorafenib) at screening. 2. Patient has HBV or HCV 3. Patient has a known HIV positive diagnosis. 4. Patient has congestive heart failure Class III/IV 5. Patient has had previous exposure to belinostat.